Amphastar Pharmaceuticals (AMPH) Financials

$25.07 +0.28 (+1.13%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$25.08 +0.00 (+0.02%)

As of 08:03 AM Eastern

Annual Income Statements for Amphastar Pharmaceuticals

This table shows Amphastar Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	160	138	91	62	1.40	49	-5.74	3.65	9.82	-2.79	-11
Consolidated Net Income / (Loss)	160	138	91	63	1.10	47	-6.66	3.65	9.82	-2.79	-11
Net Income / (Loss) Continuing Operations	160	138	91	63	1.10	47	-6.66	3.65	9.82	-2.79	-11
Total Pre-Tax Income	190	171	116	84	4.64	60	-9.93	1.25	15	-10	-18
Total Operating Income	205	197	107	70	11	-0.04	-8.62	-1.27	15	-6.90	-18
Total Gross Profit	374	351	249	200	143	132	107	91	104	77	51
Total Revenue	732	644	499	438	350	322	295	240	255	252	210
Operating Revenue	732	644	499	438	350	322	295	240	255	252	210
Total Cost of Revenue	358	293	250	238	207	190	188	150	151	174	159
Operating Cost of Revenue	358	293	250	238	207	190	188	150	151	174	159
Total Operating Expenses	168	154	141	130	132	132	116	92	89	84	69
Selling, General & Admin Expense	57	52	45	51	50	50	50	44	42	42	35
Marketing Expense	38	29	22	17	15	13	8.16	6.46	5.47	5.47	5.56
Research & Development Expense	74	74	75	61	67	69	58	44	42	37	29
Total Other Income / (Expense), net	-16	-26	8.54	14	-6.32	60	-1.30	2.52	-0.75	-3.47	-0.17
Interest Expense	30	27	1.85	0.89	0.37	0.12	0.24	0.83	1.02	0.99	0.61
Interest & Investment Income	11	5.46	1.32	0.60	0.64	1.00	0.46	0.43	0.27	0.32	0.24
Other Income / (Expense), net	4.08	-3.93	9.07	15	-6.59	59	-1.52	2.92	0.01	-2.79	0.20
Income Tax Expense	30	32	23	21	3.54	14	-3.27	-2.40	4.81	-7.58	-7.45
Other Gains / (Losses), net	-0.57	-1.98	-1.18	-0.21	0.00	-	-	-	-	-	-
Basic Earnings per Share	$3.29	$2.85	$1.88	$1.30	$0.03	$1.04	($0.12)	$0.08	$0.22	($0.06)	($0.25)
Weighted Average Basic Shares Outstanding	48.43M	48.27M	48.55M	47.78M	47.04M	46.98M	46.40M	46.11M	45.38M	44.96M	41.96M
Diluted Earnings per Share	$3.06	$2.60	$1.74	$1.25	$0.03	$0.98	($0.12)	$0.08	$0.21	($0.06)	($0.25)
Weighted Average Diluted Shares Outstanding	52.06M	53.00M	52.43M	49.78M	49.12M	49.91M	46.40M	48.37M	47.50M	44.96M	41.96M
Weighted Average Basic & Diluted Shares Outstanding	47.65M	48.10M	47.90M	48.15M	47.43M	46.24M	46.79M	45.60M	45.80M	46.50M	42.80M

This table shows Amphastar Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	25	38	40	38	43	36	49	26	26	34	16
Consolidated Net Income / (Loss)	25	38	40	38	43	36	49	26	26	34	16
Net Income / (Loss) Continuing Operations	25	38	40	38	43	36	49	26	26	34	16
Total Pre-Tax Income	31	44	48	50	48	41	64	33	34	41	23
Total Operating Income	37	45	57	55	48	54	73	37	33	38	23
Total Gross Profit	85	87	102	95	90	96	108	73	74	71	59
Total Revenue	171	187	191	182	172	178	181	146	140	135	120
Operating Revenue	171	187	191	182	172	178	181	146	140	135	120
Total Cost of Revenue	85	100	89	87	82	82	72	73	66	64	62
Operating Cost of Revenue	85	100	89	87	82	82	72	73	66	64	62
Total Operating Expenses	48	42	45	40	42	42	36	36	40	33	35
Selling, General & Admin Expense	16	13	15	13	16	13	13	12	13	11	12
Marketing Expense	12	10	9.00	9.01	9.37	8.62	6.41	6.72	7.11	5.47	4.78
Research & Development Expense	20	18	21	18	17	20	17	17	20	17	19
Total Other Income / (Expense), net	-6.43	-1.18	-9.37	-4.97	-0.13	-13	-9.04	-4.09	0.14	3.43	-0.63
Interest Expense	6.29	6.43	6.70	8.61	8.61	9.46	14	3.60	0.40	0.53	0.57
Interest & Investment Income	2.09	2.29	2.43	3.34	2.56	2.30	1.20	1.03	0.92	0.58	0.33
Other Income / (Expense), net	-2.23	2.95	-5.09	0.30	5.92	-5.48	3.46	-1.52	-0.39	3.38	-0.40
Income Tax Expense	5.58	6.00	7.25	12	4.13	4.67	14	6.38	6.75	7.29	6.56
Other Gains / (Losses), net	0.00	-	0.00	0.00	-0.57	-0.51	-0.39	-0.30	-0.79	-0.06	-0.16
Basic Earnings per Share	$0.53	$0.79	$0.83	$0.77	$0.90	$0.76	$1.01	$0.54	$0.54	$0.71	$0.32
Weighted Average Basic Shares Outstanding	47.64M	48.43M	48.62M	48.91M	48.21M	48.27M	48.70M	48.40M	48M	48.55M	48.90M
Diluted Earnings per Share	$0.51	$0.74	$0.78	$0.73	$0.81	$0.70	$0.91	$0.49	$0.50	$0.64	$0.30
Weighted Average Diluted Shares Outstanding	49.89M	52.06M	51.86M	52.05M	53.01M	53.00M	53.92M	53.10M	51.97M	52.43M	52.79M
Weighted Average Basic & Diluted Shares Outstanding	47.14M	47.65M	48.08M	48.68M	48.90M	48.10M	47.91M	48.86M	48.27M	47.90M	48.33M

This table details how cash moves in and out of Amphastar Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	7.31	-12	30	32	19	-13	21	-4.90	6.28	-1.75	14
Net Cash From Operating Activities	213	184	89	98	57	42	38	39	39	11	21
Net Cash From Continuing Operating Activities	213	184	89	98	57	42	38	39	39	11	21
Net Income / (Loss) Continuing Operations	160	138	91	63	1.10	47	-6.66	3.65	9.82	-2.79	-11
Consolidated Net Income / (Loss)	160	138	91	63	1.10	47	-6.66	3.65	9.82	-2.79	-11
Depreciation Expense	28	25	24	22	20	17	15	13	12	11	13
Amortization Expense	35	28	4.93	4.56	4.69	4.05	1.99	2.86	2.52	1.94	1.92
Non-Cash Adjustments To Reconcile Net Income	22	31	17	5.68	19	18	18	15	16	13	9.93
Changes in Operating Assets and Liabilities, net	-32	-38	-48	2.26	12	-44	10	5.00	-2.30	-13	7.38
Net Cash From Investing Activities	-125	-649	-33	-29	-36	-51	-42	-37	-40	-17	-40
Net Cash From Continuing Investing Activities	-125	-649	-33	-29	-36	-51	-42	-37	-40	-17	-40
Purchase of Property, Plant & Equipment	-41	-38	-24	-27	-34	-42	-47	-35	-21	-16	-20
Acquisitions	-129	-506	0.00	0.00	-	-	0.00	-	-12	-	-18
Purchase of Investments	-77	-145	-36	-17	-14	-8.82	-0.31	-5.65	-3.60	-	-
Sale of Property, Plant & Equipment	0.00	0.00	0.42	0.00	0.00	-	0.25	-	-	-	-
Sale and/or Maturity of Investments	126	39	28	19	12	0.00	0.09	3.65	3.08	-	-
Other Investing Activities, net	-4.12	1.39	-1.37	-2.61	-1.41	-0.16	0.20	-1.80	-5.13	-0.93	-0.92
Net Cash From Financing Activities	-81	454	-26	-37	-2.25	-3.78	25	-7.72	7.14	2.24	32
Net Cash From Continuing Financing Activities	-81	454	-26	-37	-2.25	-3.78	25	-7.72	7.14	2.24	32
Repayment of Debt	-9.08	-344	-2.19	-40	-8.40	-6.78	-5.71	-9.71	-15	-8.99	-54
Repurchase of Common Equity	-85	-58	-40	-29	-24	-22	-25	-31	-9.91	-9.87	-2.27
Issuance of Debt	18	845	0.00	70	7.52	3.57	8.78	19	10	6.79	52
Issuance of Common Equity	0.00	11	16	16	23	22	47	14	22	14	38
Other Financing Activities, net	-4.85	0.00	0.00	-54	-0.11	0.00	0.00	-	-	-	-1.11
Effect of Exchange Rate Changes	-0.19	-0.28	-0.22	-0.22	0.35	-0.10	-0.27	0.50	0.08	2.25	0.85
Cash Interest Paid	27	18	3.02	2.11	2.20	2.44	2.38	1.88	1.72	1.94	2.61
Cash Income Taxes Paid	40	49	44	8.10	3.41	5.72	0.34	4.88	3.40	0.15	0.44

This table details how cash moves in and out of Amphastar Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	31	-41	2.50	-12	57	-127	120	-26	21	-1.15	-8.91
Net Cash From Operating Activities	35	29	60	69	55	24	64	55	40	15	20
Net Cash From Continuing Operating Activities	35	29	60	69	55	24	64	55	40	15	20
Net Income / (Loss) Continuing Operations	25	38	40	38	43	36	49	26	26	34	16
Consolidated Net Income / (Loss)	25	38	40	38	43	36	49	26	26	34	16
Depreciation Expense	7.37	7.26	7.22	6.96	6.82	6.65	6.44	5.87	6.25	6.20	6.20
Amortization Expense	8.60	8.13	7.96	9.63	9.28	10	12	4.34	1.20	1.16	1.37
Non-Cash Adjustments To Reconcile Net Income	11	1.24	12	5.94	3.29	11	2.05	10	7.09	3.48	3.64
Changes in Operating Assets and Liabilities, net	-17	-26	-7.33	8.64	-7.27	-40	-5.74	8.48	-0.20	-30	-6.71
Net Cash From Investing Activities	10	-36	-35	-70	15	-103	-31	-509	-6.33	-0.23	-15
Net Cash From Continuing Investing Activities	10	-36	-35	-70	15	-103	-31	-509	-6.33	-0.23	-15
Purchase of Property, Plant & Equipment	-11	-12	-14	-6.04	-8.79	-9.44	-10	-9.05	-9.48	-6.31	-5.62
Purchase of Investments	-7.09	-29	-25	-	-23	-92	-33	-9.20	-11	-5.19	-19
Sale and/or Maturity of Investments	28	7.48	5.26	66	47	-0.18	14	11	14	13	9.07
Other Investing Activities, net	-0.02	-1.47	-1.06	-0.64	-0.96	-1.67	4.00	-0.59	-0.35	-1.23	-0.15
Net Cash From Financing Activities	-15	-34	-23	-11	-14	-47	87	428	-14	-16	-14
Net Cash From Continuing Financing Activities	-15	-34	-23	-11	-14	-47	87	428	-14	-16	-14
Repayment of Debt	-0.46	-0.09	-0.63	-8.01	-0.35	-51	-211	-82	-0.97	-0.13	-0.84
Repurchase of Common Equity	-11	-42	-35	-8.50	0.00	-	-50	-0.13	-8.02	-18	-14
Issuance of Debt	1.64	4.87	9.51	-0.03	4.08	-	345	500	0.00	-	-
Other Financing Activities, net	-4.69	3.39	3.26	5.82	-17	-	-	4.57	-4.57	-	-
Effect of Exchange Rate Changes	0.12	-0.01	-0.06	-0.02	-0.10	-0.24	-0.04	-0.02	0.02	0.02	-0.10
Cash Interest Paid	7.58	4.42	8.53	5.23	8.63	5.48	9.33	1.53	1.25	1.06	0.79
Cash Income Taxes Paid	-0.90	11	12	17	0.35	47	0.81	0.99	0.34	9.28	11

This table presents Amphastar Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	1,577	1,513	742	672	631	587	514	451	428	390	389
Total Current Assets	534	490	378	318	280	255	220	188	184	176	198
Cash & Equivalents	152	144	156	126	93	74	86	66	72	66	68
Restricted Cash	2.44	2.44	2.44	2.44	4.07	4.16	4.16	4.16	1.39	1.29	1.50
Short-Term Investments	70	113	20	10	13	12	2.83	2.64	0.53	-	-
Accounts Receivable	136	115	89	79	66	45	52	36	27	33	23
Inventories, net	154	106	104	93	97	111	69	64	80	71	82
Prepaid Expenses	18	9.06	7.56	7.27	6.78	9.54	5.49	9.75	3.27	4.44	3.68
Other Current Assets	1.75	0.53	0.17	0.13	0.39	0.31	0.05	6.04	0.02	0.24	0.27
Plant, Property, & Equipment, net	297	283	238	244	260	234	210	181	153	142	138
Total Noncurrent Assets	746	741	125	109	91	98	83	83	91	72	53
Long-Term Investments	11	15	2.41	3.99	-	-	-	-	-	-	-
Noncurrent Note & Lease Receivables	0.38	0.56	0.75	0.35	0.61	0.89	-	-	-	-	-
Goodwill	591	613	37	39	41	41	42	45	50	40	43
Noncurrent Deferred & Refundable Income Taxes	71	53	39	22	25	26	31	29	31	27	6.93
Other Noncurrent Operating Assets	73	58	46	44	25	30	9.92	8.66	9.39	4.70	3.59
Total Liabilities & Shareholders' Equity	1,577	1,513	742	672	631	587	514	451	428	390	389
Total Liabilities	845	873	213	226	183	159	149	117	98	95	108
Total Current Liabilities	174	225	95	104	112	90	107	67	61	60	63
Short-Term Debt	0.23	0.44	3.05	2.20	12	7.74	18	6.31	5.37	11	7.59
Accounts Payable	157	93	84	90	96	77	87	58	48	14	10
Accrued Expenses	0.00	126	0.00	-	-	-	-	-	-	17	13
Current Deferred & Payable Income Tax Liabilities	9.66	1.61	4.57	9.08	1.08	2.04	1.19	3.33	7.71	3.08	4.32
Other Current Liabilities	6.80	3.91	3.00	2.98	3.36	3.18	-	-	-	1.86	1.92
Total Noncurrent Liabilities	671	648	118	122	70	69	42	50	38	35	45
Long-Term Debt	602	590	73	75	34	39	32	41	32	30	36
Noncurrent Deferred Revenue	6.96	6.07	7.23	6.53	4.71	3.43	0.42	0.88	0.85	1.84	2.48
Other Noncurrent Operating Liabilities	63	52	38	40	31	26	8.94	7.06	3.21	2.67	0.49
Total Equity & Noncontrolling Interests	732	639	529	446	449	428	364	334	329	296	282
Total Preferred & Common Equity	732	639	529	446	402	381	332	334	329	296	282
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	732	639	529	446	402	381	332	334	329	296	282
Common Stock	505	486	455	422	410	367	344	314	283	248	221
Retained Earnings	569	409	272	180	118	116	67	73	71	60	63
Treasury Stock	-333	-247	-190	-150	-122	-98	-75	-51	-20	-10	-0.35
Accumulated Other Comprehensive Income / (Loss)	-9.18	-8.48	-8.62	-6.77	-3.72	-4.69	-4.01	-2.10	-4.70	-2.48	-1.65

This table presents Amphastar Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,626	1,545	1,492	1,574	1,545	1,378	774	727
Total Current Assets	588	546	483	555	543	385	408	384
Cash & Equivalents	183	192	190	201	267	149	177	157
Restricted Cash	2.44	2.44	2.44	2.44	6.46	4.89	2.44	2.44
Short-Term Investments	54	58	28	88	33	15	16	27
Accounts Receivable	145	140	131	138	119	105	101	77
Inventories, net	185	130	122	115	110	105	104	103
Prepaid Expenses	18	18	7.95	8.70	6.20	5.87	7.33	5.99
Other Current Assets	0.76	5.35	0.67	0.78	1.51	1.33	0.73	11
Plant, Property, & Equipment, net	308	295	288	289	281	279	243	233
Total Noncurrent Assets	731	704	721	731	721	715	123	110
Long-Term Investments	5.91	0.00	9.94	15	2.00	1.46	1.76	2.69
Noncurrent Note & Lease Receivables	0.34	0.43	0.47	0.52	0.61	0.66	0.71	0.60
Goodwill	585	595	601	607	619	626	37	37
Noncurrent Deferred & Refundable Income Taxes	71	53	53	53	41	41	39	22
Other Noncurrent Operating Assets	69	55	56	55	58	47	44	47
Total Liabilities & Shareholders' Equity	1,626	1,545	1,492	1,574	1,545	1,378	774	727
Total Liabilities	875	818	778	902	949	789	225	222
Total Current Liabilities	199	159	137	255	258	251	106	102
Short-Term Debt	0.22	0.25	0.25	0.43	0.43	13	2.17	1.68
Accounts Payable	176	153	131	117	223	218	89	96
Current Deferred & Payable Income Tax Liabilities	15	1.28	1.51	5.86	31	18	12	1.53
Other Current Liabilities	7.75	4.21	4.00	3.94	3.72	3.13	2.99	3.18
Total Noncurrent Liabilities	676	658	641	647	692	538	119	119
Long-Term Debt	604	596	587	594	638	488	73	74
Noncurrent Deferred Revenue	6.96	6.07	6.07	6.07	7.23	7.23	7.23	6.53
Other Noncurrent Operating Liabilities	65	56	48	47	46	42	39	39
Commitments & Contingencies	0.00	-	-	0.00	-	-	0.00	-
Total Equity & Noncontrolling Interests	751	728	713	672	595	589	549	505
Total Preferred & Common Equity	751	728	713	672	595	589	549	505
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	751	728	713	672	595	589	549	505
Common Stock	509	496	488	476	478	471	457	449
Retained Earnings	594	531	490	452	373	324	298	238
Treasury Stock	-344	-291	-256	-247	-247	-197	-198	-171
Accumulated Other Comprehensive Income / (Loss)	-7.97	-8.82	-8.83	-8.77	-8.41	-8.32	-8.27	-9.93

This table displays calculated financial ratios and metrics derived from Amphastar Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.59%	29.14%	13.98%	25.13%	8.53%	9.40%	22.69%	-5.87%	1.45%	19.51%	-8.37%
EBITDA Growth	10.76%	69.46%	30.70%	276.24%	-63.28%	1,161.89%	-63.48%	-41.92%	744.44%	206.78%	-110.73%
EBIT Growth	8.51%	65.62%	38.07%	1,832.32%	-92.64%	685.36%	-714.48%	-89.27%	258.73%	45.50%	-198.80%
NOPAT Growth	8.05%	87.05%	62.55%	1,935.60%	8,705.51%	99.50%	-62.90%	-135.90%	313.74%	61.64%	-204.53%
Net Income Growth	15.98%	50.51%	44.37%	5,670.37%	-97.64%	798.27%	-282.62%	-62.86%	452.35%	73.95%	-190.20%
EPS Growth	17.69%	49.43%	39.20%	4,066.67%	-96.94%	916.67%	-250.00%	-61.90%	450.00%	76.00%	-180.65%
Operating Cash Flow Growth	16.28%	105.76%	-8.99%	71.12%	37.12%	9.35%	-2.60%	1.68%	261.01%	-49.26%	-20.70%
Free Cash Flow Firm Growth	107.88%	-999.14%	-29.93%	2,513.10%	103.52%	-240.46%	3.74%	-48.51%	26.38%	55.42%	81.54%
Invested Capital Growth	15.09%	125.27%	11.74%	-1.58%	0.09%	19.89%	4.13%	5.40%	8.71%	5.08%	11.99%
Revenue Q/Q Growth	1.16%	7.16%	2.92%	6.05%	3.72%	-1.92%	11.04%	-1.29%	-4.98%	9.13%	0.00%
EBITDA Q/Q Growth	-0.63%	7.25%	11.37%	50.49%	-25.62%	2.23%	50.83%	27.35%	-32.98%	127.67%	0.00%
EBIT Q/Q Growth	-0.19%	3.92%	13.69%	79.99%	-72.15%	0.86%	14.88%	181.89%	-50.08%	63.59%	0.00%
NOPAT Q/Q Growth	-4.68%	11.03%	18.48%	44.70%	-45.60%	-102.16%	28.64%	-26.64%	-57.09%	75.62%	0.00%
Net Income Q/Q Growth	1.14%	1.67%	18.33%	67.69%	-85.65%	-2.03%	13.45%	844.29%	-52.80%	78.30%	0.00%
EPS Q/Q Growth	1.32%	2.36%	16.00%	73.61%	-76.92%	-6.67%	14.29%	900.00%	-53.33%	79.31%	0.00%
Operating Cash Flow Q/Q Growth	2.48%	4.94%	-22.04%	31.63%	24.42%	-8.47%	-0.65%	-9.76%	38.50%	-45.83%	65.18%
Free Cash Flow Firm Q/Q Growth	-18.44%	4.80%	-38.89%	37.09%	118.53%	-9.98%	4.71%	-219.01%	35.37%	0.00%	0.00%
Invested Capital Q/Q Growth	2.58%	3.19%	8.24%	-1.89%	-1.96%	2.36%	1.42%	0.98%	-3.18%	4.39%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	51.08%	54.49%	49.87%	45.63%	40.97%	40.92%	36.31%	37.68%	40.83%	30.75%	24.35%
EBITDA Margin	37.26%	38.21%	29.12%	25.40%	8.45%	24.96%	2.16%	7.27%	11.78%	1.42%	-1.58%
Operating Margin	28.06%	30.57%	21.54%	15.96%	3.13%	-0.01%	-2.93%	-0.53%	6.03%	-2.74%	-8.54%
EBIT Margin	28.62%	29.96%	23.36%	19.28%	1.25%	18.41%	-3.44%	0.69%	6.03%	-3.85%	-8.45%
Profit (Net Income) Margin	21.79%	21.34%	18.31%	14.46%	0.31%	14.43%	-2.26%	1.52%	3.85%	-1.11%	-5.08%
Tax Burden Percent	84.06%	80.27%	78.75%	75.23%	23.66%	77.21%	67.10%	291.99%	67.12%	26.89%	58.95%
Interest Burden Percent	90.58%	88.76%	99.55%	99.66%	106.13%	101.48%	97.90%	75.70%	95.10%	106.93%	102.06%
Effective Tax Rate	15.64%	18.58%	20.23%	24.52%	76.34%	22.79%	0.00%	-191.99%	32.88%	0.00%	0.00%
Return on Invested Capital (ROIC)	16.87%	23.26%	21.35%	13.79%	0.67%	-0.01%	-1.92%	-1.23%	3.67%	-1.84%	-5.19%
ROIC Less NNEP Spread (ROIC-NNEP)	12.83%	1.59%	14.75%	-2.52%	3.50%	-108.88%	-0.09%	-25.04%	5.27%	-9.71%	-13.00%
Return on Net Nonoperating Assets (RNNOA)	6.38%	0.29%	-2.59%	0.36%	-0.42%	11.75%	0.01%	2.33%	-0.53%	0.87%	1.18%
Return on Equity (ROE)	23.26%	23.55%	18.76%	14.16%	0.25%	11.75%	-1.91%	1.10%	3.14%	-0.97%	-4.01%
Cash Return on Invested Capital (CROIC)	2.84%	-53.76%	10.26%	15.38%	0.58%	-18.10%	-5.96%	-6.49%	-4.67%	-6.79%	-16.50%
Operating Return on Assets (OROA)	13.56%	17.12%	16.49%	12.96%	0.72%	10.79%	-2.10%	0.38%	3.76%	-2.49%	-4.88%
Return on Assets (ROA)	10.32%	12.20%	12.93%	9.72%	0.18%	8.45%	-1.38%	0.83%	2.40%	-0.72%	-2.94%
Return on Common Equity (ROCE)	23.26%	23.55%	18.76%	13.42%	0.22%	10.59%	-1.82%	1.10%	3.14%	-0.97%	-4.01%
Return on Equity Simple (ROE_SIMPLE)	21.78%	21.51%	17.29%	14.21%	0.27%	12.19%	-2.00%	1.09%	2.98%	-0.94%	-3.80%
Net Operating Profit after Tax (NOPAT)	173	160	86	53	2.59	-0.03	-6.04	-3.71	10	-4.83	-13
NOPAT Margin	23.68%	24.89%	17.18%	12.05%	0.74%	-0.01%	-2.05%	-1.54%	4.04%	-1.92%	-5.98%
Net Nonoperating Expense Percent (NNEP)	4.04%	21.67%	6.60%	16.31%	-2.83%	108.87%	-1.83%	23.80%	-1.59%	7.87%	7.81%
Return On Investment Capital (ROIC_SIMPLE)	12.99%	13.05%	14.18%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	48.92%	45.51%	50.13%	54.37%	59.03%	59.08%	63.69%	62.32%	59.17%	69.25%	75.65%
SG&A Expenses to Revenue	7.75%	8.00%	9.03%	11.75%	14.40%	15.60%	16.93%	18.51%	16.39%	16.50%	16.54%
R&D to Revenue	10.10%	11.44%	14.98%	13.92%	19.22%	21.36%	19.54%	18.11%	16.27%	14.82%	13.72%
Operating Expenses to Revenue	23.01%	23.92%	28.33%	29.66%	37.84%	40.94%	39.23%	38.21%	34.81%	33.49%	32.90%
Earnings before Interest and Taxes (EBIT)	209	193	117	84	4.37	59	-10	1.65	15	-9.69	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	273	246	145	111	30	80	6.38	17	30	3.56	-3.33
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.44	4.63	2.56	2.50	2.37	2.37	2.76	2.65	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	12.60	113.41	2.76	2.74	2.64	2.66	3.16	3.07	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.44	4.60	2.71	2.55	2.73	2.81	3.11	3.68	0.00	0.00	0.00
Price to Earnings (P/E)	11.19	21.54	14.82	17.94	680.90	18.50	0.00	242.55	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.94%	4.64%	6.75%	5.57%	0.15%	5.41%	0.00%	0.41%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.96	3.43	2.95	2.76	2.43	2.36	2.82	2.79	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.94	5.09	2.50	2.39	2.68	2.82	3.08	3.58	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	7.89	13.32	8.60	9.43	31.76	11.30	142.10	49.22	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	10.27	16.98	10.72	12.42	214.81	15.32	0.00	520.82	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	12.42	20.44	14.57	19.87	362.15	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	10.09	17.87	14.01	10.70	16.39	21.77	23.73	21.92	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	73.71	0.00	30.31	17.82	416.84	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.82	0.92	0.14	0.17	0.10	0.11	0.14	0.14	0.11	0.14	0.16
Long-Term Debt to Equity	0.82	0.92	0.14	0.17	0.08	0.09	0.09	0.12	0.10	0.10	0.13
Financial Leverage	0.50	0.18	-0.18	-0.14	-0.12	-0.11	-0.10	-0.09	-0.10	-0.09	-0.09
Leverage Ratio	2.25	1.93	1.45	1.46	1.39	1.39	1.38	1.33	1.31	1.35	1.37
Compound Leverage Factor	2.04	1.71	1.44	1.45	1.48	1.41	1.35	1.00	1.24	1.44	1.39
Debt to Total Capital	45.11%	47.99%	12.55%	14.73%	9.38%	9.93%	12.11%	12.38%	10.28%	12.21%	13.42%
Short-Term Debt to Total Capital	0.02%	0.04%	0.50%	0.42%	2.48%	1.63%	4.40%	1.66%	1.46%	3.25%	2.33%
Long-Term Debt to Total Capital	45.09%	47.96%	12.05%	14.31%	6.90%	8.30%	7.71%	10.72%	8.82%	8.96%	11.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	9.37%	9.73%	7.70%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.89%	52.01%	87.45%	85.27%	81.25%	80.34%	80.19%	87.62%	89.72%	87.79%	86.58%
Debt to EBITDA	2.21	2.40	0.52	0.69	1.57	0.59	7.87	2.70	1.25	11.54	-13.11
Net Debt to EBITDA	1.34	1.28	-0.72	-0.59	-2.14	-0.53	-6.76	-1.44	-1.22	-7.38	7.69
Long-Term Debt to EBITDA	2.21	2.39	0.50	0.67	1.16	0.49	5.02	2.34	1.08	8.47	-10.83
Debt to NOPAT	3.47	3.68	0.89	1.46	17.92	-1,565.23	-8.32	-12.73	3.66	-8.51	-3.47
Net Debt to NOPAT	2.12	1.97	-1.22	-1.25	-24.40	1,407.33	7.14	6.81	-3.54	5.44	2.04
Long-Term Debt to NOPAT	3.47	3.68	0.85	1.42	13.19	-1,308.17	-5.30	-11.02	3.14	-6.25	-2.87
Altman Z-Score	2.95	3.47	5.97	4.78	4.30	4.91	4.65	5.61	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	5.19%	10.57%	9.86%	4.57%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.07	2.17	3.99	3.06	2.49	2.84	2.06	2.79	3.04	2.93	3.16
Quick Ratio	2.06	1.65	2.79	2.08	1.53	1.45	1.32	1.55	1.64	1.66	1.45
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	29	-371	41	59	2.25	-64	-19	-20	-13	-18	-40
Operating Cash Flow to CapEx	519.93%	480.80%	377.68%	356.91%	169.15%	100.50%	82.02%	111.71%	180.34%	66.77%	102.70%
Free Cash Flow to Firm to Interest Expense	0.96	-13.65	22.33	66.48	6.02	-537.22	-77.27	-23.62	-12.83	-18.08	-65.71
Operating Cash Flow to Interest Expense	7.03	6.76	48.31	110.73	153.12	350.94	157.16	47.47	37.66	10.82	34.57
Operating Cash Flow Less CapEx to Interest Expense	5.68	5.35	35.52	79.70	62.60	1.74	-34.45	4.98	16.78	-5.39	0.91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.57	0.71	0.67	0.57	0.59	0.61	0.55	0.62	0.65	0.58
Accounts Receivable Turnover	5.83	6.33	5.95	6.05	6.28	6.61	6.68	7.65	8.50	8.97	8.87
Inventory Turnover	2.76	2.80	2.55	2.51	1.99	2.12	2.82	2.09	2.01	2.28	2.09
Fixed Asset Turnover	2.52	2.47	2.07	1.74	1.42	1.45	1.51	1.44	1.73	1.79	1.65
Accounts Payable Turnover	2.86	3.30	2.88	2.57	2.39	2.32	2.59	2.85	4.92	14.49	10.43
Days Sales Outstanding (DSO)	62.64	57.70	61.30	60.37	58.10	55.22	54.60	47.70	42.92	40.69	41.13
Days Inventory Outstanding (DIO)	132.28	130.32	143.29	145.40	183.23	172.33	129.26	174.81	181.84	160.31	174.53
Days Payable Outstanding (DPO)	127.62	110.52	126.80	141.88	152.50	157.62	140.97	128.16	74.25	25.18	35.01
Cash Conversion Cycle (CCC)	67.30	77.50	77.79	63.89	88.84	69.94	42.89	94.35	150.51	175.83	180.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,099	955	424	379	385	385	321	309	293	269	256
Invested Capital Turnover	0.71	0.93	1.24	1.14	0.91	0.91	0.94	0.80	0.91	0.96	0.87
Increase / (Decrease) in Invested Capital	144	531	45	-6.08	0.34	64	13	16	23	13	27
Enterprise Value (EV)	2,152	3,279	1,250	1,048	938	909	906	859	0.00	0.00	0.00
Market Capitalization	1,785	2,963	1,354	1,114	955	905	917	885	0.00	0.00	0.00
Book Value per Share	$15.23	$13.35	$10.94	$9.31	$8.47	$8.12	$7.21	$7.26	$7.26	$6.57	$6.72
Tangible Book Value per Share	$2.95	$0.55	$10.17	$8.50	$7.61	$7.25	$6.29	$6.28	$6.15	$5.69	$5.70
Total Capital	1,334	1,229	605	523	495	475	415	381	367	337	326
Total Debt	602	590	76	77	46	47	50	47	38	41	44
Total Long-Term Debt	602	590	73	75	34	39	32	41	32	30	36
Net Debt	367	316	-105	-66	-63	-42	-43	-25	-37	-26	-26
Capital Expenditures (CapEx)	41	38	24	27	34	42	47	35	21	16	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	136	5.39	108	77	70	83	38	55	55	60	74
Debt-free Net Working Capital (DFNWC)	361	265	287	217	180	173	132	127	129	127	143
Net Working Capital (NWC)	360	264	283	214	167	165	114	121	123	116	135
Net Nonoperating Expense (NNE)	14	23	-5.64	-11	1.49	-47	0.62	-7.35	0.50	-2.04	-1.89
Net Nonoperating Obligations (NNO)	367	316	-105	-66	-63	-42	-43	-25	-37	-26	-26
Total Depreciation and Amortization (D&A)	63	53	29	27	25	21	17	16	15	13	14
Debt-free, Cash-free Net Working Capital to Revenue	18.64%	0.84%	21.71%	17.68%	20.03%	25.89%	13.04%	22.70%	21.39%	23.68%	35.01%
Debt-free Net Working Capital to Revenue	49.26%	41.07%	57.42%	49.46%	51.38%	53.66%	44.71%	52.84%	50.49%	50.46%	67.94%
Net Working Capital to Revenue	49.23%	41.00%	56.81%	48.95%	47.87%	51.26%	38.52%	50.21%	48.39%	46.11%	64.34%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.29	$2.85	$1.88	$1.30	$0.03	$1.04	($0.12)	$0.10	$0.23	($0.06)	($0.25)
Adjusted Weighted Average Basic Shares Outstanding	48.43M	48.27M	48.55M	47.78M	47.04M	46.98M	46.40M	46.11M	45.38M	44.96M	41.96M
Adjusted Diluted Earnings per Share	$3.06	$2.60	$1.74	$1.25	$0.03	$0.98	($0.12)	$0.09	$0.22	($0.06)	($0.25)
Adjusted Weighted Average Diluted Shares Outstanding	52.06M	53.00M	52.43M	49.78M	49.12M	49.91M	46.40M	48.37M	47.50M	44.96M	41.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47.65M	48.10M	47.90M	48.15M	47.43M	46.24M	46.79M	46.35M	45.91M	44.91M	44.56M
Normalized Net Operating Profit after Tax (NOPAT)	173	160	86	53	7.67	-0.03	-6.04	-2.74	10	-4.83	-13
Normalized NOPAT Margin	23.68%	24.89%	17.18%	12.05%	2.19%	-0.01%	-2.05%	-1.14%	4.04%	-1.92%	-5.98%
Pre Tax Income Margin	25.93%	26.59%	23.26%	19.22%	1.33%	18.68%	-3.37%	0.52%	5.73%	-4.12%	-8.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	6.90	7.11	63.14	95.39	11.68	498.74	-41.72	2.00	15.02	-9.82	-29.20
NOPAT to Interest Expense	5.71	5.91	46.45	59.61	6.93	-0.25	-24.84	-4.49	10.08	-4.89	-20.67
EBIT Less CapEx to Interest Expense	5.55	5.70	50.35	64.37	-78.84	149.54	-233.34	-40.50	-5.86	-26.03	-62.86
NOPAT Less CapEx to Interest Expense	4.36	4.50	33.66	28.58	-83.59	-349.45	-216.46	-46.98	-10.80	-21.10	-54.33
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	53.57%	42.27%	43.67%	45.61%	2,226.53%	47.93%	-376.08%	843.08%	100.90%	-353.96%	-21.17%

This table displays calculated financial ratios and metrics derived from Amphastar Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.76%	4.73%	5.90%	25.17%	22.72%	31.91%	50.30%	18.02%	16.33%	11.69%	7.07%
EBITDA Growth	-27.13%	-2.63%	-29.29%	58.14%	72.90%	34.26%	212.32%	50.27%	12.49%	44.00%	-31.75%
EBIT Growth	-34.99%	-0.83%	-31.76%	56.91%	63.21%	17.69%	233.48%	51.72%	13.13%	51.65%	-39.97%
NOPAT Growth	-30.36%	-18.58%	-14.63%	40.34%	64.26%	53.72%	243.70%	57.48%	43.76%	74.71%	-19.07%
Net Income Growth	-41.44%	4.97%	-17.86%	45.26%	65.86%	6.65%	210.08%	50.61%	7.34%	71.62%	-48.73%
EPS Growth	-37.04%	5.71%	-14.29%	48.98%	62.00%	9.38%	203.33%	48.48%	6.38%	60.00%	-49.15%
Operating Cash Flow Growth	-36.56%	21.62%	-6.80%	25.83%	36.92%	56.73%	215.75%	1,851.08%	-20.45%	-62.35%	693.11%
Free Cash Flow Firm Growth	75.48%	78.24%	79.54%	78.68%	-1,238.36%	-3,511.87%	-4,225.19%	-202,747.37%	-210.07%	-155.95%	-56.89%
Invested Capital Growth	15.68%	15.09%	15.78%	16.22%	124.99%	125.27%	136.30%	138.38%	17.41%	11.74%	1.27%
Revenue Q/Q Growth	-8.58%	-2.45%	4.84%	6.14%	-3.52%	-1.36%	23.91%	4.06%	3.70%	12.40%	-2.70%
EBITDA Q/Q Growth	-19.62%	-5.43%	-6.89%	2.96%	7.40%	-31.33%	108.25%	12.58%	-16.61%	59.75%	0.20%
EBIT Q/Q Growth	-27.10%	-7.43%	-6.41%	2.94%	11.20%	-36.30%	115.20%	7.07%	-19.81%	80.49%	-2.09%
NOPAT Q/Q Growth	-21.63%	-19.40%	15.98%	-4.94%	-8.37%	-15.50%	90.66%	11.27%	-14.25%	88.94%	-12.64%
Net Income Q/Q Growth	-33.40%	-6.10%	6.54%	-12.11%	19.38%	-26.52%	88.42%	0.35%	-23.24%	113.64%	-8.49%
EPS Q/Q Growth	-31.08%	-5.13%	6.85%	-9.88%	15.71%	-23.08%	85.71%	-2.00%	-21.88%	113.33%	-9.09%
Operating Cash Flow Q/Q Growth	20.86%	-51.60%	-13.24%	24.99%	131.69%	-62.91%	17.13%	36.01%	165.22%	-25.27%	623.80%
Free Cash Flow Firm Q/Q Growth	-14.10%	-7.66%	9.29%	78.00%	-1.25%	-1.26%	5.50%	-1,281.19%	-173.26%	-215.66%	4,747.04%
Invested Capital Q/Q Growth	1.01%	2.58%	0.11%	11.53%	0.49%	3.19%	0.49%	115.92%	0.61%	8.24%	1.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	49.99%	46.45%	53.31%	52.18%	52.43%	53.98%	60.04%	49.92%	52.73%	52.71%	48.71%
EBITDA Margin	29.92%	34.03%	35.11%	39.53%	40.75%	36.61%	52.58%	31.29%	28.92%	35.97%	25.31%
Operating Margin	21.87%	24.20%	29.83%	30.27%	27.94%	30.31%	40.25%	25.32%	23.88%	28.02%	19.34%
EBIT Margin	20.56%	25.79%	27.17%	30.44%	31.39%	27.23%	42.17%	24.28%	23.60%	30.52%	19.01%
Profit (Net Income) Margin	14.83%	20.35%	21.14%	20.81%	25.13%	20.31%	27.26%	17.93%	18.59%	25.12%	13.21%
Tax Burden Percent	81.93%	86.36%	84.79%	75.53%	90.19%	87.48%	77.35%	79.63%	77.55%	82.19%	70.25%
Interest Burden Percent	88.03%	91.41%	91.78%	90.50%	88.77%	85.25%	83.58%	92.73%	101.59%	100.13%	98.97%
Effective Tax Rate	18.07%	13.64%	15.21%	24.47%	8.62%	11.30%	22.04%	19.46%	20.11%	17.67%	29.03%
Return on Invested Capital (ROIC)	12.65%	14.90%	18.33%	16.37%	24.91%	25.13%	28.65%	16.88%	25.05%	28.66%	17.10%
ROIC Less NNEP Spread (ROIC-NNEP)	11.02%	14.60%	15.98%	15.28%	24.07%	14.02%	21.79%	13.59%	25.62%	25.42%	17.88%
Return on Net Nonoperating Assets (RNNOA)	5.00%	7.26%	8.14%	8.08%	3.26%	2.53%	4.29%	2.73%	-5.94%	-4.46%	-3.00%
Return on Equity (ROE)	17.65%	22.16%	26.47%	24.45%	28.17%	27.66%	32.95%	19.61%	19.11%	24.20%	14.10%
Cash Return on Invested Capital (CROIC)	0.88%	2.84%	3.59%	4.10%	-51.19%	-53.76%	-59.12%	-65.85%	7.64%	10.26%	17.33%
Operating Return on Assets (OROA)	9.39%	12.21%	12.73%	15.12%	18.08%	15.56%	22.33%	12.50%	16.43%	21.55%	13.37%
Return on Assets (ROA)	6.77%	9.64%	9.90%	10.34%	14.47%	11.61%	14.43%	9.23%	12.94%	17.73%	9.30%
Return on Common Equity (ROCE)	17.65%	22.16%	26.47%	24.45%	28.17%	27.66%	32.95%	19.61%	19.11%	24.20%	14.10%
Return on Equity Simple (ROE_SIMPLE)	18.85%	0.00%	21.67%	23.34%	23.01%	0.00%	22.73%	17.30%	16.98%	0.00%	15.29%
Net Operating Profit after Tax (NOPAT)	31	39	48	42	44	48	57	30	27	31	16
NOPAT Margin	17.92%	20.90%	25.30%	22.87%	25.53%	26.88%	31.38%	20.39%	19.07%	23.07%	13.72%
Net Nonoperating Expense Percent (NNEP)	1.63%	0.30%	2.36%	1.09%	0.84%	11.11%	6.86%	3.29%	-0.57%	3.24%	-0.78%
Return On Investment Capital (ROIC_SIMPLE)	2.25%	2.92%	-	-	-	3.89%	-	-	-	5.15%	-
Cost of Revenue to Revenue	50.01%	53.55%	46.69%	47.82%	47.57%	46.02%	39.96%	50.08%	47.27%	47.29%	51.29%
SG&A Expenses to Revenue	9.38%	6.94%	7.75%	7.28%	9.12%	7.37%	7.01%	8.43%	9.63%	7.87%	9.98%
R&D to Revenue	11.78%	9.73%	11.02%	9.68%	9.92%	11.46%	9.23%	11.56%	14.15%	12.77%	15.41%
Operating Expenses to Revenue	28.12%	22.25%	23.48%	21.90%	24.49%	23.67%	19.79%	24.60%	28.86%	24.69%	29.37%
Earnings before Interest and Taxes (EBIT)	35	48	52	56	54	48	76	35	33	41	23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	51	63	67	72	70	65	95	46	40	49	30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.84	2.44	3.25	2.74	3.14	4.63	3.78	4.71	3.27	2.56	2.73
Price to Tangible Book Value (P/TBV)	8.28	12.60	17.78	17.39	32.35	113.41	0.00	0.00	3.51	2.76	2.94
Price to Revenue (P/Rev)	1.89	2.44	3.26	2.74	3.12	4.60	3.74	5.13	3.46	2.71	2.84
Price to Earnings (P/E)	9.75	11.19	14.98	11.75	13.65	21.54	16.61	27.21	19.28	14.82	17.83
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	10.25%	8.94%	6.68%	8.51%	7.32%	4.64%	6.02%	3.67%	5.19%	6.75%	5.61%
Enterprise Value to Invested Capital (EV/IC)	1.57	1.96	2.53	2.16	2.50	3.43	2.78	3.37	3.92	2.95	3.23
Enterprise Value to Revenue (EV/Rev)	2.38	2.94	3.74	3.24	3.55	5.09	4.29	5.74	3.23	2.50	2.61
Enterprise Value to EBITDA (EV/EBITDA)	6.86	7.89	9.86	7.65	8.70	13.32	11.22	18.82	11.18	8.60	9.69
Enterprise Value to EBIT (EV/EBIT)	9.13	10.27	12.89	9.88	11.21	16.98	13.87	23.45	13.90	10.72	12.33
Enterprise Value to NOPAT (EV/NOPAT)	10.90	12.42	14.88	12.17	13.46	20.44	17.84	29.82	17.92	14.57	17.46
Enterprise Value to Operating Cash Flow (EV/OCF)	9.01	10.09	13.00	10.88	12.09	17.87	14.74	23.73	21.25	14.01	11.05
Enterprise Value to Free Cash Flow (EV/FCFF)	190.67	73.71	75.59	56.70	0.00	0.00	0.00	0.00	55.48	30.31	18.73
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.80	0.82	0.82	0.82	0.88	0.92	1.07	0.85	0.14	0.14	0.15
Long-Term Debt to Equity	0.80	0.82	0.82	0.82	0.88	0.92	1.07	0.83	0.13	0.14	0.15
Financial Leverage	0.45	0.50	0.51	0.53	0.14	0.18	0.20	0.20	-0.23	-0.18	-0.17
Leverage Ratio	2.25	2.25	2.34	2.20	1.92	1.93	2.06	1.93	1.45	1.45	1.47
Compound Leverage Factor	1.98	2.06	2.14	1.99	1.71	1.65	1.73	1.79	1.47	1.45	1.46
Debt to Total Capital	44.57%	45.11%	45.06%	45.15%	46.92%	47.99%	51.76%	45.96%	12.03%	12.55%	13.03%
Short-Term Debt to Total Capital	0.02%	0.02%	0.02%	0.02%	0.03%	0.04%	0.04%	1.18%	0.35%	0.50%	0.29%
Long-Term Debt to Total Capital	44.55%	45.09%	45.04%	45.13%	46.89%	47.96%	51.73%	44.78%	11.69%	12.05%	12.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	55.43%	54.89%	54.95%	54.85%	53.08%	52.01%	48.24%	54.04%	87.97%	87.45%	86.97%
Debt to EBITDA	2.38	2.21	2.17	1.94	2.16	2.40	2.78	3.04	0.50	0.52	0.58
Net Debt to EBITDA	1.41	1.34	1.25	1.18	1.04	1.28	1.44	2.01	-0.81	-0.72	-0.87
Long-Term Debt to EBITDA	2.38	2.21	2.17	1.94	2.15	2.39	2.78	2.96	0.49	0.50	0.57
Debt to NOPAT	3.78	3.47	3.28	3.09	3.33	3.68	4.42	4.81	0.80	0.89	1.05
Net Debt to NOPAT	2.25	2.12	1.89	1.88	1.61	1.97	2.29	3.18	-1.31	-1.22	-1.57
Long-Term Debt to NOPAT	3.78	3.47	3.28	3.09	3.33	3.68	4.42	4.69	0.78	0.85	1.02
Altman Z-Score	2.27	2.61	3.09	2.85	2.58	3.16	2.53	3.03	6.61	5.64	5.43
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.95	3.07	3.43	3.52	2.18	2.17	2.11	1.53	3.86	3.99	3.76
Quick Ratio	1.92	2.06	2.45	2.55	1.68	1.65	1.62	1.07	2.78	2.79	2.56
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-120	-105	-98	-108	-489	-483	-477	-505	-37	-13	12
Operating Cash Flow to CapEx	327.91%	233.86%	434.73%	1,143.43%	628.81%	252.74%	631.16%	606.62%	426.11%	241.30%	362.35%
Free Cash Flow to Firm to Interest Expense	-19.08	-16.36	-14.58	-12.50	-56.81	-51.10	-34.82	-140.17	-91.85	-25.34	20.44
Operating Cash Flow to Interest Expense	5.58	4.52	8.95	8.03	6.42	2.52	4.70	15.25	101.46	28.84	36.00
Operating Cash Flow Less CapEx to Interest Expense	3.88	2.59	6.89	7.33	5.40	1.53	3.95	12.73	77.65	16.89	26.06
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.47	0.47	0.50	0.58	0.57	0.53	0.51	0.70	0.71	0.70
Accounts Receivable Turnover	5.17	5.83	5.60	6.04	5.66	6.33	6.13	5.83	5.97	5.95	6.25
Inventory Turnover	2.40	2.76	2.83	2.85	2.82	2.80	2.58	2.60	2.53	2.55	2.47
Fixed Asset Turnover	2.45	2.52	2.51	2.52	2.54	2.47	2.34	2.10	2.13	2.07	2.04
Accounts Payable Turnover	2.47	2.86	1.81	1.85	3.00	3.30	1.73	1.68	2.73	2.88	2.72
Days Sales Outstanding (DSO)	70.62	62.64	65.23	60.45	64.44	57.70	59.51	62.60	61.16	61.30	58.41
Days Inventory Outstanding (DIO)	151.88	132.28	128.90	128.24	129.50	130.32	141.42	140.24	144.10	143.29	148.00
Days Payable Outstanding (DPO)	147.67	127.62	201.70	197.00	121.49	110.52	211.25	217.38	133.88	126.80	134.34
Cash Conversion Cycle (CCC)	74.83	67.30	-7.56	-8.31	72.45	77.50	-10.32	-14.54	71.38	77.79	72.07
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,110	1,099	1,071	1,070	960	955	925	921	427	424	392
Invested Capital Turnover	0.71	0.71	0.72	0.72	0.98	0.93	0.91	0.83	1.31	1.24	1.25
Increase / (Decrease) in Invested Capital	150	144	146	149	533	531	534	535	63	45	4.92
Enterprise Value (EV)	1,740	2,152	2,706	2,313	2,399	3,279	2,577	3,106	1,674	1,250	1,264
Market Capitalization	1,381	1,785	2,362	1,956	2,112	2,963	2,247	2,774	1,796	1,354	1,377
Book Value per Share	$15.77	$15.23	$14.95	$14.59	$13.98	$13.35	$12.18	$12.21	$11.45	$10.94	$10.31
Tangible Book Value per Share	$3.50	$2.95	$2.73	$2.30	$1.36	$0.55	($0.50)	($0.75)	$10.68	$10.17	$9.55
Total Capital	1,355	1,334	1,324	1,300	1,267	1,229	1,234	1,090	624	605	581
Total Debt	604	602	597	587	594	590	639	501	75	76	76
Total Long-Term Debt	604	602	596	587	594	590	638	488	73	73	74
Net Debt	359	367	344	357	287	316	330	332	-122	-105	-114
Capital Expenditures (CapEx)	11	12	14	6.04	8.79	9.44	10	9.05	9.48	6.31	5.62
Debt-free, Cash-free Net Working Capital (DFCFNWC)	150	136	134	126	8.35	5.39	-21	-22	109	108	97
Debt-free Net Working Capital (DFNWC)	389	361	387	346	300	265	285	146	304	287	284
Net Working Capital (NWC)	389	360	387	346	300	264	285	133	302	283	282
Net Nonoperating Expense (NNE)	5.27	1.02	7.94	3.76	0.70	12	7.44	3.59	0.68	-2.77	0.61
Net Nonoperating Obligations (NNO)	359	367	344	357	287	316	330	332	-122	-105	-114
Total Depreciation and Amortization (D&A)	16	15	15	17	16	17	19	10	7.46	7.36	7.57
Debt-free, Cash-free Net Working Capital to Revenue	20.50%	18.64%	18.56%	17.63%	1.23%	0.84%	-3.47%	-4.04%	20.99%	21.71%	20.05%
Debt-free Net Working Capital to Revenue	53.26%	49.26%	53.51%	48.52%	44.41%	41.07%	47.48%	27.03%	58.65%	57.42%	58.52%
Net Working Capital to Revenue	53.23%	49.23%	53.48%	48.49%	44.35%	41.00%	47.40%	24.64%	58.24%	56.81%	58.17%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.53	$0.79	$0.83	$0.77	$0.90	$0.76	$1.01	$0.54	$0.54	$0.71	$0.32
Adjusted Weighted Average Basic Shares Outstanding	47.64M	48.43M	48.62M	48.91M	48.21M	48.27M	48.70M	48.40M	48M	48.55M	48.90M
Adjusted Diluted Earnings per Share	$0.51	$0.74	$0.78	$0.73	$0.81	$0.70	$0.91	$0.49	$0.50	$0.64	$0.30
Adjusted Weighted Average Diluted Shares Outstanding	49.89M	52.06M	51.86M	52.05M	53.01M	53.00M	53.92M	53.10M	51.97M	52.43M	52.79M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47.14M	47.65M	48.08M	48.68M	48.90M	48.10M	47.91M	48.86M	48.27M	47.90M	48.33M
Normalized Net Operating Profit after Tax (NOPAT)	31	39	48	42	44	48	57	30	27	31	16
Normalized NOPAT Margin	17.92%	20.90%	25.30%	22.87%	25.53%	26.88%	31.38%	20.39%	19.07%	23.07%	13.72%
Pre Tax Income Margin	18.10%	23.57%	24.94%	27.55%	27.86%	23.21%	35.25%	22.52%	23.97%	30.56%	18.81%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.58	7.49	7.76	6.45	6.26	5.13	5.56	9.82	83.02	78.05	40.34
NOPAT to Interest Expense	4.86	6.07	7.22	4.84	5.09	5.06	4.14	8.25	67.11	58.99	29.13
EBIT Less CapEx to Interest Expense	3.88	5.55	5.70	5.75	5.24	4.13	4.81	7.31	59.21	66.09	30.40
NOPAT Less CapEx to Interest Expense	3.16	4.14	5.16	4.14	4.07	4.06	3.39	5.74	43.29	47.04	19.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	68.11%	53.57%	27.55%	35.13%	32.41%	42.27%	56.33%	39.93%	50.12%	43.67%	45.67%

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

When does Amphastar Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Amphastar Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Amphastar Pharmaceuticals' net income changed over the last 10 years?

Amphastar Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $159.52 million in 2024, falling from -$10.70 million in 2014. The previous period was $137.55 million in 2023. Check out Amphastar Pharmaceuticals' forecast to explore projected trends and price targets.

What is Amphastar Pharmaceuticals's operating income?

Amphastar Pharmaceuticals's total operating income in 2024 was $205.42 million, based on the following breakdown:

Total Gross Profit: $373.86 million
Total Operating Expenses: $168.44 million

How has Amphastar Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Amphastar Pharmaceuticals' total revenue changed from $210.46 million in 2014 to $731.97 million in 2024, a change of 247.8%.

How much debt does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals' total liabilities were at $845.17 million at the end of 2024, a 3.2% decrease from 2023, and a 686.1% increase since 2014.

How much cash does Amphastar Pharmaceuticals have?

In the past 10 years, Amphastar Pharmaceuticals' cash and equivalents has ranged from $65.59 million in 2017 to $156.10 million in 2022, and is currently $151.61 million as of their latest financial filing in 2024.

How has Amphastar Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Amphastar Pharmaceuticals' book value per share changed from 6.72 in 2014 to 15.23 in 2024, a change of 126.7%.

Related Companies

This page (NASDAQ:AMPH) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Financials

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Financials

Annual Income Statements for Amphastar Pharmaceuticals

Quarterly Income Statements for Amphastar Pharmaceuticals

Annual Cash Flow Statements for Amphastar Pharmaceuticals

Quarterly Cash Flow Statements for Amphastar Pharmaceuticals

Annual Balance Sheets for Amphastar Pharmaceuticals

Quarterly Balance Sheets for Amphastar Pharmaceuticals

Annual Metrics And Ratios for Amphastar Pharmaceuticals

Quarterly Metrics And Ratios for Amphastar Pharmaceuticals

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools